Evidence map›Paper›PMID 41317318›Full record

Trial reportTransfusion2026

Amustaline/glutathione pathogen-reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial.

Ian J Welsby, Michael E Sekela, Edward L Snyder, James D Gorham, John S McNeil, Kathy Liu, Stanley Bentow, Thomas Gniadek, Laurence Corash, Nina Mufti and 2 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ian J WelsbyDuke University Medical Center, Durham, North Carolina, USA.
Michael E SekelaGill Heart Institute, University of Kentucky, Lexington, Kentucky, USA.
Edward L SnyderYale University School of Medicine, New Haven, Connecticut, USA.
James D GorhamUniversity of Virginia Health System, Charlottesville, Virginia, USA.ORCID https://orcid.org/0000-0003-3711-2607
John S McNeilUniversity of Virginia Health System, Charlottesville, Virginia, USA.
Kathy LiuCerus Corporation, Concord, California, USA.
Stanley BentowCerus Corporation, Concord, California, USA.
Thomas GniadekCerus Corporation, Concord, California, USA.
Laurence CorashCerus Corporation, Concord, California, USA.
Nina MuftiCerus Corporation, Concord, California, USA.
Richard J BenjaminCerus Corporation, Concord, California, USA.
ReCePI Study Group

Funding

Biomedical Advanced Research and Development Authority HHS010020160009c
6 · The paper itself

Abstract

backgroundThe ReCePI randomized, controlled trial compared amustaline/glutathione pathogen-reduced (PR) and conventional red blood cell (RBC) transfusions in cardiac surgery. STUDY DESIGN AND

methodsWe performed a post-hoc analysis of hemoglobin (Hb) utilization and safety outcomes. Hb content of study RBCs was measured at manufacture. Subject Hb levels, estimated blood loss and blood product use were recorded during and for 7 days post-surgery. Acute kidney injury (AKI) incidence was graded over 7 days, and adverse events were assessed for 28 days.

resultsPR-RBCs contained 5.2% less Hb (mean [SD] Test 58.1 [6.5] g; Control 61.5 [6.8] g Hb, p < .001) due to manufacturing volume losses. Four hundred fifty-six PR- and 524 conventional RBCs were transfused to 159 Test and 162 Control subjects, respectively. Mean subject baseline and post-surgery Hb levels, and blood loss were not different between groups. Test subjects tended to require fewer total RBCs (3.5 [2.7] Test vs. 4.0 [3.5] Control, p = .08) resulting in 17.6% significantly less mean total Hb transfused (Test 203.2 g; Control 246.8 g Hb, p = .01). The proportions of subjects transfused with, and the number of platelet and cryoprecipitate units transfused were not different. Test subjects received less plasma (2.3 [1.8] units Test vs. 3.5 [3.8] Control, p = .03). Overall incidence of adverse events and AKI were not clinically different. Imbalances in AKI severity (Grade III Test 15/159 [9.4%]; Control 7/162 [4.3%], p = .07) may suggest under-transfusion in the highest-risk Test subjects. DISCUSSION: Test patients required less transfused Hb than control subjects to maintain equivalent daily hemoglobin levels following similar blood loss.

Indexed as

Cardiac Surgical ProceduresErythrocyte TransfusionGlutathioneHemoglobinsAcridinesAcute Kidney InjuryAgedBlood Loss, SurgicalErythrocytesFemaleHumansMaleMiddle AgedNitrogen Mustard CompoundsAcridinesGlutathioneHemoglobinsNitrogen Mustard Compounds(N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionateacute kidney injuryAmustalinecardiac surgeryKDIGOpathogen reductionred blood cells

Identifiers

PMID41317318
PMCPMC12857873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.